|
1
|
Thibodeau SN, Bren G and Schaid D:
Microsatellite instability in cancer of the proximal colon.
Science. 260:816–819. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karamurzin Y and Rutgers JK: DNA mismatch
repair deficiency in endometrial carcinoma. Int J Gynecol Pathol.
28:239–255. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Murali R, Soslow RA and Weigelt B:
Classification of endometrial carcinoma: More than two types.
Lancet Oncol. 15:e268–e278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garg K and Soslow RA: Lynch syndrome
(hereditary non-polyposis colorectal cancer) and endometrial
carcinoma. J Clin Pathol. 62:679–684. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dedes KJ, Wetterskog D, Ashworth A, Kaye
SB and Reis-Filho JS: Emerging therapeutic targets in endometrial
cancer. Nat Rev Clin Oncol. 8:261–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matias-Guiu X and Prat J: Molecular
pathology of endometrial carcinoma. Histopathology. 62:111–123.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salvesen HB, Haldorsen IS and Trovik J:
Markers for individualised therapy in endometrial carcinoma. Lancet
Oncol. 13:e353–e361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weigelt B and Banerjee S: Molecular
targets and targeted therapeutics in endometrial cancer. Curr Opin
Oncol. 24:554–563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McConechy MK, Ding J, Cheang MC, Wiegand
KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, et al: Use
of mutation profiles to refine the classification of endometrial
carcinomas. J Pathol. 228:20–30. 2012.PubMed/NCBI
|
|
12
|
Urick ME, Rudd ML, Godwin AK, Sgroi D,
Merino M and Bell DW: PIK3R1 (p85α) is somatically mutated at high
frequency in primary endometrial cancer. Cancer Res. 71:4061–4067.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cancer Genome Atlas Research Network, .
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Le Gallo M and Bell DW: The emerging
genomic landscape of endometrial cancer. Clin Chem. 60:98–110.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okazaki T and Honjo T: PD-1 and PD-1
ligands: From discovery to clinical application. Int Immunol.
19:813–824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hamanishi J, Mandai M, Matsumura N, Abiko
K, Baba T and Konishi I: PD-1/PD-L1 blockade in cancer treatment:
Perspectives and issues. Int J Clin Oncol. 21:462–473. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hamanishi J, Mandai M, Ikeda T, Minami M,
Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S,
et al: Safety and antitumor activity of anti-PD-1 antibody,
nivolumab, in patients with platinum-resistant ovarian cancer. J
Clin Oncol. 33:4015–4022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Howitt BE, Shukla SA, Sholl LM,
Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC,
D'Andrea AD, Wu CJ, et al: Association of polymerase e-mutated and
microsatellite-instable endometrial cancers with neoantigen load,
number of tumor-infiltrating lymphocytes, and expression of PD-1
and PD-L1. JAMA Oncol. 1:1319–1323. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dudley JC, Lin MT, Le DT and Eshleman JR:
Microsatellite instability as a biomarker for PD-1 blockade. Clin
Cancer Res. 22:813–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mills AM, Liou S, Ford JM, Berek JS, Pai
RK and Longacre TA: Lynch syndrome screening should be considered
for all patients with newly diagnosed endometrial cancer. Am J Surg
Pathol. 38:1501–1509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mlecnik B, Bindea G, Angell HK, Maby P,
Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M,
Fredriksen T, et al: Integrative analyses of colorectal cancer show
immunoscore is a stronger predictor of patient survival than
microsatellite instability. Immunity. 44:698–711. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Meng X, Huang Z, Teng F, Xing L and Yu J:
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade
immunotherapy. Cancer Treat Rev. 41:868–876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
de la Chapelle A and Hampel H: Clinical
relevance of microsatellite instability in colorectal cancer. J
Clin Oncol. 28:3380–3387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Buhard O, Suraweera N, Lectard A, Duval A
and Hamelin R: Quasimonomorphic mononucleotide repeats for
high-level microsatellite instability analysis. Dis Markers.
20:251–257. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu Y, Berends MJ, Mensink RG, Kempinga C,
Sijmons RH, van Der Zee AG, Hollema H, Kleibeuker JH, Buys CH and
Hofstra RM: Association of hereditary nonpolyposis colorectal
cancer-related tumors displaying low microsatellite instability
with MSH6 germline mutations. Am J Hum Genet. 65:1291–1298. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hartmann A, Zanardo L, Bocker-Edmonston T,
Blaszyk H, Dietmaier W, Stoehr R, Cheville JC, Junker K, Wieland W,
Knuechel R, et al: Frequent microsatellite instability in sporadic
tumors of the upper urinary tract. Cancer Res. 62:6796–6802.
2002.PubMed/NCBI
|
|
31
|
Kuismanen SA, Moisio AL, Schweizer P,
Truninger K, Salovaara R, Arola J, Butzow R, Jiricny J,
Nyström-Lahti M and Peltomäki P: Endometrial and colorectal tumors
from patients with hereditary nonpolyposis colon cancer display
different patterns of microsatellite instability. Am J Pathol.
160:1953–1958. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hendriks YM, Wagner A, Morreau H, Menko F,
Stormorken A, Quehenberger F, Sandkuijl L, Møller P, Genuardi M,
Van Houwelingen H, et al: Cancer risk in hereditary nonpolyposis
colorectal cancer due to MSH6 mutations: Impact on counseling and
surveillance. Gastroenterology. 127:17–25. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
You JF, Buhard O, Ligtenberg MJ, Kets CM,
Niessen RC, Hofstra RM, Wagner A, Dinjens WN, Colas C, Lascols O,
et al: Tumours with loss of MSH6 expression are MSI-H when screened
with a pentaplex of five mononucleotide repeats. Br J Cancer.
103:1840–1845. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Suraweera N, Duval A, Reperant M, Vaury C,
Furlan D, Leroy K, Seruca R, Iacopetta B and Hamelin R: Evaluation
of tumor microsatellite instability using five quasimonomorphic
mononucleotide repeats and pentaplex PCR. Gastroenterology.
123:1804–1811. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Umar A, Boland CR, Terdiman JP, Syngal S,
de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ,
Hamelin R, et al: Revised Bethesda Guidelines for hereditary
nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite
instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wong YF, Cheung TH, Lo KW, Yim SF, Chan
LK, Buhard O, Duval A, Chung TK and Hamelin R: Detection of
microsatellite instability in endometrial cancer: Advantages of a
panel of five mononucleotide repeats over the National Cancer
Institute panel of markers. Carcinogenesis. 27:951–955. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xicola RM, Llor X, Pons E, Castells A,
Alenda C, Piñol V, Andreu M, Castellví-Bel S, Payá A, Jover R, et
al: Performance of different microsatellite marker panels for
detection of mismatch repair-deficient colorectal tumors. J Natl
Cancer Inst. 99:244–252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Goel A, Nagasaka T, Hamelin R and Boland
CR: An optimized pentaplex PCR for detecting DNA mismatch
repair-deficient colorectal cancers. PLoS One. 5:e93932010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Buhard O, Cattaneo F, Wong YF, Yim SF,
Friedman E, Flejou JF, Duval A and Hamelin R: Multipopulation
analysis of polymorphisms in five mononucleotide repeats used to
determine the microsatellite instability status of human tumors. J
Clin Oncol. 24:241–251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pagin A, Zerimech F, Leclerc J, Wacrenier
A, Lejeune S, Descarpentries C, Escande F, Porchet N and Buisine
MP: Evaluation of a new panel of six mononucleotide repeat markers
for the detection of DNA mismatch repair-deficient tumours. Br J
Cancer. 108:2079–2087. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hause RJ, Pritchard CC, Shendure J and
Salipante SJ: Classification and characterization of microsatellite
instability across 18 cancer types. Nat Med. 22:1342–1350. 2016.
View Article : Google Scholar : PubMed/NCBI
|
